About Ventyx Biosciences, Inc.
https://www.ventyxbio.comVentyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders.
CEO
Raju S. Mohan
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 48
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:4.77M
Value:$66.14M
AFFINITY ASSET ADVISORS, LLC
Shares:3.92M
Value:$54.39M
VANGUARD GROUP INC
Shares:3.77M
Value:$52.25M
Summary
Showing Top 3 of 123
About Ventyx Biosciences, Inc.
https://www.ventyxbio.comVentyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $24.87M ▼ | $-22.83M ▲ | 0% | $-0.32 ▲ | $-22.77M ▲ |
| Q2-2025 | $0 | $29.33M ▼ | $-26.99M ▲ | 0% | $-0.38 ▲ | $-29.01M ▲ |
| Q1-2025 | $0 | $30.1M ▼ | $-27.44M ▲ | 0% | $-0.39 ▲ | $-29.74M ▲ |
| Q4-2024 | $0 | $32.42M ▼ | $-29.35M ▲ | 0% | $-0.41 ▲ | $-32.1M ▲ |
| Q3-2024 | $0 | $38.55M | $-35.25M | 0% | $-0.5 | $-38.24M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $192.64M ▼ | $211.47M ▼ | $20.1M ▼ | $191.36M ▼ |
| Q2-2025 | $208.96M ▼ | $230.01M ▼ | $20.63M ▼ | $209.38M ▼ |
| Q1-2025 | $228.81M ▲ | $253.48M ▼ | $21.85M ▼ | $231.63M ▼ |
| Q4-2024 | $217.32M ▼ | $276.56M ▼ | $22.52M ▲ | $254.04M ▼ |
| Q3-2024 | $274.82M | $301.1M | $22.33M | $278.77M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-22.83M ▲ | $-17.51M ▲ | $17.05M ▼ | $203K ▲ | $-331K ▼ | $-17.56M ▲ |
| Q2-2025 | $-26.99M ▲ | $-21.28M ▲ | $25.19M ▼ | $68K ▲ | $4.22M ▲ | $-21.32M ▲ |
| Q1-2025 | $-27.44M ▲ | $-25.72M ▼ | $26.41M ▲ | $0 ▲ | $816K ▲ | $-25.73M ▼ |
| Q4-2024 | $-29.35M ▲ | $-23.25M ▲ | $-11M ▼ | $-25K ▼ | $-34.51M ▼ | $-23.25M ▲ |
| Q3-2024 | $-35.25M | $-35.46M | $29.25M | $26.86M | $20.84M | $-35.46M |
CEO
Raju S. Mohan
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 48
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:4.77M
Value:$66.14M
AFFINITY ASSET ADVISORS, LLC
Shares:3.92M
Value:$54.39M
VANGUARD GROUP INC
Shares:3.77M
Value:$52.25M
Summary
Showing Top 3 of 123